XML 53 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies - Summary of Significant Accounts Receivable (Detail) (Accounts Receivable [Member])
 9 Months Ended 12 Months Ended
Sep. 30, 2013
Dec. 31, 2012
Dec. 31, 2011
Gilead [Member]
      
Concentration Risk [Line Items]      
Significant Accounts Receivable 51.20%      
Pfizer [Member]
      
Concentration Risk [Line Items]      
Significant Accounts Receivable 22.60% 45.40% 28.00%
Boehringer [Member]
      
Concentration Risk [Line Items]      
Significant Accounts Receivable 11.10% 18.00% 40.10%
Eli Lilly [Member]
      
Concentration Risk [Line Items]      
Significant Accounts Receivable 11.00% 28.20% 10.60%
Government Agencies [Member]
      
Concentration Risk [Line Items]      
Significant Accounts Receivable 4.00% 8.40% 21.30%